NASDAQ:ANIX
Anixa Biosciences Inc
Anixa Biosciences Inc reported net income of −$10.9M in fiscal 2025. The diluted share count rose 1.7%.Summary generated from Anixa Biosciences Inc's SEC filings. Latest annual report filed Jan 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−62.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+1.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | n/a | 0 | 0 | n/a |
| Operating income | −13 | −14 | −11 | −14 | −12 |
| Net income | −13 | −14 | −10 | −13 | −11 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 30, 2026 - 4Insider transaction report
Sep 28, 2026 - 10-QQuarterly report for the period ended Jul 31, 2026
Sep 9, 2026 - 10-QQuarterly report for the period ended Apr 30, 2026
Jun 10, 2026 - 8-KResults of a shareholder vote
Mar 11, 2026 - 10-QQuarterly report for the period ended Jan 31, 2026
Mar 9, 2026 - 8-KRegulation FD disclosure
Feb 9, 2026 - DEF 14AProxy statement
Jan 28, 2026